Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | TTR | P02766 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | MMP2 | P08253 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | THRB | P10828 | 2/20 | 0.72 |
| ▸ | MMP9 | P14780 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958569 | 1.00 | LCK (0.81) | LCKKDM4EALOX5CYP3A4ALDH1A1 | |
| SCHEMBL4607867 | 1.00 | LCK (0.81) | LCKKDM4EALOX5CYP3A4ALDH1A1 | |
| SCHEMBL30631591 | 0.90 | LCK (1.00) | LCKKDM4EALOX5CYP3A4ALDH1A1 | |
| SCHEMBL31706727 | 0.90 | LCK (1.00) | LCKKDM4EALOX5CYP3A4ALDH1A1 | |
| SCHEMBL1824175 | 0.90 | LCK (1.00) | LCKKDM4EALOX5CYP3A4ALDH1A1 | |
| SCHEMBL1824176 | 0.90 | LCK (1.00) | LCKKDM4EALOX5CYP3A4ALDH1A1 | |
| SCHEMBL10335571 | 0.87 | LCK (0.94) | LCKKDM4EALOX5CYP3A4ALDH1A1 | |
| SCHEMBL4608757 | 0.84 | PTGS2 (0.54) | LCKKDM4EALOX5CYP3A4ALDH1A1 | |
| SCHEMBL4608754 | 0.84 | PTGS2 (0.54) | LCKKDM4EALOX5CYP3A4ALDH1A1 | |
| SCHEMBL1932873 | 0.84 | LCK (0.91) | LCKKDM4EALOX5CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313010-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | Szekeres, Thomas (AT) | 2024-02-07 | — | — | EP | claimed |
| WO-2022200086-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | SZEKERES THOMAS (AT) | 2022-09-29 | — | — | WO | claimed |
| EP-1654210-B1 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2008-07-30 | — | — | EP | claimed |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | SZEKERES THOMAS | 2007-08-16 | — | — | US | claimed |
| EP-1654210-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | Szekeres, Thomas (AT) | 2006-05-10 | — | — | EP | claimed |
| US-7026518-B2 | Resveratrol analogs | LAILA IMPEX (IN) | 2006-04-11 | — | — | US | claimed |
| WO-2005102298-A1 | MEDICAL SUBSTANCE MIXTURES CONTAINING RESVERATROL OR RESVERATROL-DERIVATIVES, IN ADDITION TO THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-11-03 | — | — | WO | claimed |
| WO-2005016860-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-02-24 | — | — | WO | claimed |
| US-20040209951-A1 | Novel resveratrol analogs | LAILA IMPEX (IN) | 2004-10-21 | — | — | US | claimed |
| EP-4313010-B1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | SZEKERES THOMAS (AT) | 2025-02-19 | — | — | EP | disclosed |
| US-20240166587-A1 | SARS-CoV-2 inhibitors - artificial compounds | SZEKERES THOMAS (AT) | 2024-05-23 | — | — | US | disclosed |
| EP-4313010-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | Szekeres, Thomas (AT) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022200086-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | SZEKERES THOMAS (AT) | 2022-09-29 | — | — | WO | disclosed |
| EP-1976487-A2 | SUSTAINED RELEASE DOSAGE FORM OF PHENOTHIAZINE DERIVATIVES CONTAINING CHANNELIZER | Astron Research Limited (IN) | 2008-10-08 | — | — | EP | disclosed |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | SZEKERES THOMAS | 2007-08-16 | — | — | US | disclosed |
| WO-2007086079-A2 | SUSTAINED RELEASE DOSAGE FORM OF PHENOTHIAZINE DERIVATIVES CONTAINING CHANNELIZER | ASTRON RESEARCH LIMITED (IN) | 2007-08-02 | — | — | WO | disclosed |
| EP-1654210-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | Szekeres, Thomas (AT) | 2006-05-10 | — | — | EP | disclosed |
| US-7026518-B2 | Resveratrol analogs | LAILA IMPEX (IN) | 2006-04-11 | — | — | US | disclosed |
| WO-2005016860-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-02-24 | — | — | WO | disclosed |
| US-20040209951-A1 | Novel resveratrol analogs | LAILA IMPEX (IN) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166587-A1 | SARS-CoV-2 inhibitors - artificial compounds | ACE2, ACE, FURIN | LCK 3127/4885KDM4E 2886/4885ALOX5 2295/4885 |
| US-20040209951-A1 | Novel resveratrol analogs | HRH1, CBR1, CBR3 | LCK 4349/4885KDM4E 1415/4885ALOX5 1966/4885 |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | PTGS2, PTGS1, PTGER2 | LCK 3040/4885KDM4E 3574/4885ALOX5 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.